NCT07117890View on ClinicalTrials.gov

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

PHASE2RecruitingINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

February 20, 2027

Study Completion Date

May 30, 2027

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Sunvozertinib

sunvozertinib 300mg QD

Trial Locations (1)

Unknown

RECRUITING

Fudan university shanghai cancer center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER